Theratechnologies (TH) Stock Price, News & Analysis

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: C$1.67 to C$1.73
• 50-Day Range: C$1.60 to C$1.93
• 52-Week Range: C$1.59 to C$3.43
• Volume: 6,100 shs
• Average Volume: 29,736 shs
• Market Capitalization: C$77.25 million
• P/E Ratio: N/A
• Dividend Yield: 3.76%
• Price Target: N/A
• Consensus Rating: Buy

TH Stock Analysis - Frequently Asked Questions

How have TH shares performed this year?

Theratechnologies' stock was trading at C$2.14 on January 1st, 2024. Since then, TH shares have decreased by 20.1% and is now trading at C$1.71.
View the best growth stocks for 2024 here.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (TSE:TH) issued its quarterly earnings results on Thursday, October, 10th. The company reported $0.09 EPS for the quarter. The company had revenue of $30.96 million for the quarter. Theratechnologies had a negative trailing twelve-month return on equity of 1,116.86% and a negative net margin of 8.47%.

How do I buy shares of Theratechnologies?

Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include Theratechnologies (THTX), Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Vanguard Extended Duration Treasury ETF (EDV) and Nemaska Lithium (NMX).

Company Calendar

• Last Earnings: 10/10/2024
• Today: 11/21/2024
• Next Earnings (Estimated): 2/19/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Restaurants, Hotels, Motels
• Current Symbol: TSE:TH
• CUSIP: N/A
• CIK: N/A
• Web: www.theratech.com
• Phone: +1-514-3367800
• Fax: N/A
• Employees: 103
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 56.92
• P/E Growth: -8.5
• Net Income: C$-7,000,000.00
• Net Margins: -8.47%
• Pretax Margin: N/A
• Return on Equity: -1,116.86%
• Return on Assets: 5.15%

Debt

• Debt-to-Equity Ratio: 562.07
• Current Ratio: 1.10
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: C$82.57 million
• Price / Sales: 0.95
• Cash Flow: C$0.45 per share
• Price / Cash Flow: 3.76
• Book Value: C($0.50) per share
• Price / Book: -3.40

Miscellaneous

• Outstanding Shares: 45,980,000
• Free Float: N/A
• Market Cap: C$78.17 million
• Optionable: Not Optionable
• Beta: 1.73